The Utility of Micro-RNA

MicroRNAs have demonstrated roles in human development, where their expression can drive or maintain tissue phenotype. Correspondingly their aberrant expression is a significant driver of the pathophysiology of many chronic diseases including diabetes and cancer. miRNA's are recognised as being highly stable ex vivo and miRNA signatures can be obtained from samples with poor ribosome integrity number (RIN) values. When this is combined with their undisputed biological importance it makes miRNA’s attractive biomarker candidates for a wide range of applications.

The utility of miRNA provides a means to generate cost-effective, information-rich cell characterisation tools and biomarkers for use in the Bioprocessing, Cell and Stem Cell Therapy, and Drug Discovery and Development markets. Click to find out how our innovative miRNA products can help you

About Sistemic

Sistemic is a development-stage biomedical company focused on the analysis of the information content of microRNA and other non-coding RNAs for applications in the development of cell therapies and drug repositioning. Sistemic’s patented and proprietary technology platforms provide a novel way to apply the information content of miRNA’s to overcome key obstacles to creating clinically useful stem cell therapies.

Recent News

Sistemic Ltd announce expansion of patent portfolio covering the use of microRNAs for quality assessment of stem cell therapy products by the granting of “Cell Characterisation” European patent No. EP2609217

Release Date: March 28, 2019

Sistemic Ltd announce expansion of patent portfolio covering the use of microRNAs for quality assessment of stem cell therapy products by the granting of “Cell Characterisation” European patent No. EP2609217

The European Patent Office communicated its decision to grant European Patent No. EP2609217, in the name of Sistemic Scotland Ltd titled “Cell Characterisation”.

The patent covers the use of microRNA profiles for quality assessment of stem cells and derived cell therapy products.

The successful development of Sistemic’s SistemPSCCheck™ assay is featured as case studies on both the Innovate UK Analysis for Innovators website and the National Measurement Laboratory for Chemical and Bio-Measurement at LGC website

Release Date: March 25, 2019

SistemPSCCheck™ is a first-in-class miRNA-based assay, for high sensitivity assessment of residual undifferentiated PSCs in derived cell preparations. SistemPSCCheck™ is a safety and batch release assay service to support the clinical and commercial development of pluripotent stem cell-derived cell therapy products.

SistemPSCCheck™ was developed in conjunction with National Measurement Laboratory for Chemical and Bio-Measurement at LGC and was supported by the UK’s innovation agency, Innovate UK, under the “Analysis for Innovators” grant.

Sistemic Ltd announce expansion of patent portfolio covering the use of microRNAs for quality assessment of stem cell therapy products

Release Date: January 28, 2019

Glasgow, United Kingdom; 28th January 2019: Sistemic Ltd. is pleased to announce that it has received Notification of Intention to Grant by the European Patent Office for the patent application entitled “Cell Characterisation” (European Patent Application No 11760806.7).

The patent covers the use of microRNA profiles for quality assessment of stem cells and derived cell therapy products.